Global Implantable Drug-Eluting Devices Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Product;

Implantable Drug Infusion Pumps, Intraocular Drug-Eluting Devices, Contraceptive Drug-Eluting Devices, Buprenorphine Implant, Drug-Eluting Stents and Others.

By Technology;

Active Drug Eluting Device, Passive Drug Eluting Device-Biodegradable Implants, Non-Biodegradable Implants.

By Application;

Diabetes Macular Edema, Birth Control/Contraception, Opioid Addiction, Cardiovascular, Ophthalmology, Oncology and Pain Management.

By Implantation;

Intravaginal, Intravascular, Intraocular, Intrathecal, Subcutaneous and Intrauterine.

By End User;

Hospitals, Ambulatory Surgical Centers, Optical Care Centers, Cardiac Surgery Centers, Office-Based Settings, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn758964364 Published Date: April, 2025 Updated Date: May, 2025

Introduction

Global Implantable Drug-Eluting Devices Market (USD Million), 2021 - 2031

In the year 2024, the Global Implantable Drug-Eluting Devices Market was valued at USD 15,750.92 million. The size of this market is expected to increase to USD 23,683.55 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.0%.


Global Implantable Drug-Eluting Devices Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 6.0 %


Study Period2025 - 2031
Base Year2024
CAGR (%)6.0 %
Market Size (2024)USD 15,750.92 Million
Market Size (2031)USD 23,683.55 Million
Market ConcentrationMedium
Report Pages315
15,750.92
2024
23,683.55
2031

Major Players

  • Terumo Corporation
  • Cook Medical LLC
  • Biosensors International Group, Ltd.
  • B. Braun Melsungen AG
  • Lepu Medical Technology (Beijing) Co., Ltd.

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Implantable Drug-Eluting Devices Market

Fragmented - Highly competitive market without dominant players


The global implantable drug-eluting devices market is expanding rapidly due to rising interest in long-term, site-specific drug delivery technologies. These devices enable controlled medication release directly at the treatment site, significantly minimizing systemic exposure and adverse effects. Currently, nearly 65% of long-duration therapies in chronic care settings involve drug-eluting implants, showcasing their increasing relevance in targeted medical treatments.

Chronic Disease Management Fueling Market Expansion
The rising prevalence of chronic illnesses such as cardiovascular diseases, cancer, and autoimmune disorders is driving greater reliance on advanced therapeutic devices. Drug-eluting implants are widely used to improve outcomes and reduce recurrence in such conditions. Notably, approximately 70% of coronary interventions today utilize drug-eluting stents, underscoring their value in reducing complications like restenosis.

Advances in Drug-Eluting Technologies
Ongoing innovation in biomaterials and controlled release mechanisms is significantly elevating the capabilities of drug-eluting implants. Over 50% of new products entering the market feature next-generation polymers or nano-enabled systems to optimize drug diffusion and duration. These technological improvements are enhancing device performance while enabling more precise and adaptable treatment protocols.

Enhanced Patient Adherence and Treatment Consistency
Implantable drug-eluting devices offer a major advantage in improving medication adherence by eliminating the need for frequent dosing. Research indicates that patient compliance improves by nearly 45% when switching from traditional administration methods to implant-based delivery. This results in more consistent drug exposure and better long-term therapeutic outcomes across various disease areas.

Innovation and Collaboration Driving Industry Growth
Market participants are increasingly focusing on research partnerships and strategic investments to develop advanced drug-eluting solutions. Over the last three years, more than 40% of collaborative R&D efforts in the implantable device sector have centered on drug-eluting technologies. This reflects a growing industry emphasis on creating innovative, minimally invasive solutions for complex, chronic conditions.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Product
    2. Market Snapshot, By Technology
    3. Market Snapshot, By Application
    4. Market Snapshot, By Implantation
    5. Market Snapshot, By End User
    6. Market Snapshot, By Region
  4. Global Implantable Drug-Eluting Devices Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing prevalence of chronic diseases
        2. Growing demand for targeted drug delivery systems
        3. Advancements in technology and formulation
        4. Rise in minimally invasive procedures
        5. Focus on personalized medicine
      2. Restraints
        1. Regulatory hurdles and approval process
        2. High development and manufacturing costs
        3. Potential adverse effects and safety concerns
        4. Limited reimbursement coverage
      3. Opportunities
        1. Expansion in emerging markets
        2. Development of biodegradable and bioresorbable devices
        3. Integration of smart technologies for remote monitoring
        4. Strategic partnerships and collaborations
        5. Innovation in drug-eluting coatings and materials
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Implantable Drug-Eluting Devices Market, By Product, 2021-2031 (USD Million)
      1. Implantable Drug Infusion Pumps
      2. Intraocular Drug-Eluting Devices
      3. Contraceptive Drug-Eluting Devices
      4. Buprenorphine Implant
      5. Drug-Eluting Stents
      6. Others
    2. Global Implantable Drug-Eluting Devices Market, By Technology, 2021-2031 (USD Million)
      1. Active Drug Eluting Device
      2. Passive Drug Eluting Device
        1. Biodegradable Implants
        2. Non-Biodegradable Implants
    3. Global Implantable Drug-Eluting Devices Market, By Application, 2021-2031 (USD Million)
      1. Diabetes Macular Edema
      2. Birth Control/Contraception
      3. Opioid Addiction
      4. Cardiovascular
      5. Ophthalmology
      6. Oncology
      7. Pain Management
    4. Global Implantable Drug-Eluting Devices Market, By Implantation, 2021-2031 (USD Million)
      1. Intravaginal
      2. Intravascular
      3. Intraocular
      4. Intrathecal
      5. Subcutaneous
      6. Intrauterine
    5. Global Implantable Drug-Eluting Devices Market, By End User, 2021-2031 (USD Million)
      1. Hospitals
      2. Ambulatory Surgical Centers
      3. Optical Care Centers
      4. Cardiac Surgery Centers
      5. Office-Based Settings
      6. Others
    6. Global Implantable Drug-Eluting Devices Market, By Geography, 2021-2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN(Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Terumo Corporation
      2. Cook Medical LLC
      3. Biosensors International Group, Ltd.
      4. B. Braun Melsungen AG
      5. Lepu Medical Technology (Beijing) Co., Ltd.
  7. Analyst Views
  8. Future Outlook of the Market